These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 23604140)
1. Exploration of the orthosteric/allosteric interface in human M1 muscarinic receptors by bitopic fluorescent ligands. Daval SB; Kellenberger E; Bonnet D; Utard V; Galzi JL; Ilien B Mol Pharmacol; 2013 Jul; 84(1):71-85. PubMed ID: 23604140 [TBL] [Abstract][Full Text] [Related]
2. Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors. Daval SB; Valant C; Bonnet D; Kellenberger E; Hibert M; Galzi JL; Ilien B J Med Chem; 2012 Mar; 55(5):2125-43. PubMed ID: 22329602 [TBL] [Abstract][Full Text] [Related]
3. Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. Tahtaoui C; Parrot I; Klotz P; Guillier F; Galzi JL; Hibert M; Ilien B J Med Chem; 2004 Aug; 47(17):4300-15. PubMed ID: 15294002 [TBL] [Abstract][Full Text] [Related]
4. A fluorescence anisotropy assay for the muscarinic M1 G-protein-coupled receptor. Huwiler KG; De Rosier T; Hanson B; Vogel KW Assay Drug Dev Technol; 2010 Jun; 8(3):356-66. PubMed ID: 20233092 [TBL] [Abstract][Full Text] [Related]
5. On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies. Tahtaoui C; Guillier F; Klotz P; Galzi JL; Hibert M; Ilien B J Med Chem; 2005 Dec; 48(24):7847-59. PubMed ID: 16302823 [TBL] [Abstract][Full Text] [Related]
6. Pirenzepine promotes the dimerization of muscarinic M1 receptors through a three-step binding process. Ilien B; Glasser N; Clamme JP; Didier P; Piemont E; Chinnappan R; Daval SB; Galzi JL; Mely Y J Biol Chem; 2009 Jul; 284(29):19533-43. PubMed ID: 19451648 [TBL] [Abstract][Full Text] [Related]
7. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site. Jacobson MA; Kreatsoulas C; Pascarella DM; O'Brien JA; Sur C Mol Pharmacol; 2010 Oct; 78(4):648-57. PubMed ID: 20660086 [TBL] [Abstract][Full Text] [Related]
8. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [3H]pirenzepine and [3H]quinuclidinylbenzilate binding to rat brain membranes. Burke RE Mol Pharmacol; 1986 Jul; 30(1):58-68. PubMed ID: 3755217 [TBL] [Abstract][Full Text] [Related]
9. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor. Redka DS; Pisterzi LF; Wells JW Mol Pharmacol; 2008 Sep; 74(3):834-43. PubMed ID: 18552124 [TBL] [Abstract][Full Text] [Related]
10. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. Lanzafame AA; Sexton PM; Christopoulos A Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648 [TBL] [Abstract][Full Text] [Related]
11. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821 [TBL] [Abstract][Full Text] [Related]
12. Pharmacologic discrimination between receptor heterogeneity and allosteric interaction: resultant analysis of gallamine and pirenzepine antagonism of muscarinic responses in rat trachea. Kenakin T; Boselli C J Pharmacol Exp Ther; 1989 Sep; 250(3):944-52. PubMed ID: 2778720 [TBL] [Abstract][Full Text] [Related]
13. Dualsteric muscarinic antagonists--orthosteric binding pose controls allosteric subtype selectivity. Schmitz J; van der Mey D; Bermudez M; Klöckner J; Schrage R; Kostenis E; Tränkle C; Wolber G; Mohr K; Holzgrabe U J Med Chem; 2014 Aug; 57(15):6739-50. PubMed ID: 25051097 [TBL] [Abstract][Full Text] [Related]
14. The Role of Orthosteric Building Blocks of Bitopic Ligands for Muscarinic M1 Receptors. Volpato D; Kauk M; Messerer R; Bermudez M; Wolber G; Bock A; Hoffmann C; Holzgrabe U ACS Omega; 2020 Dec; 5(49):31706-31715. PubMed ID: 33344823 [TBL] [Abstract][Full Text] [Related]
15. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor. Keov P; Valant C; Devine SM; Lane JR; Scammells PJ; Sexton PM; Christopoulos A Mol Pharmacol; 2013 Sep; 84(3):425-37. PubMed ID: 23798605 [TBL] [Abstract][Full Text] [Related]
16. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor. Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612 [TBL] [Abstract][Full Text] [Related]